Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance
Abstract
Pathogenic germline mutations in several rare penetrant cancer predisposition genes are associated with an increased risk of aggressive prostate cancer (PC). Our objectives were to determine the prevalence of pathogenic germline mutations in men with low‐risk PC on active surveillance, and assess whether pathogenic germline mutations associate with grade reclassification or adverse pathology, recurrence, or metastases, in men treated after initial surveillance.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 25, 2022
- Source ID
- 10.1002/cam4.4778
Entities
People
- Andrew A. Wagner
- Atreya Dash
- Christopher P. Filson
- Colin C Pritchard
- Daniel W Lin
- Frances Martin
- Hilary Boyer
- Ian M. Thompson, Jr.
- James D Brooks
- Jesse K. Mckenney
- Kehao Zhu
- Lauren Brady
- Lisa F. Newcomb
- Martin E. Gleave
- Michael A Liss
- Navonil De Sarkar
- Peter R. Carroll
- Peter S Nelson
- Todd M Morgan
- William J. Ellis
- Yingye Zheng
Organizations
- Beth Israel Deaconess Medical Center
- Canary Foundation
- Congressionally Directed Medical Research Programs
- Eastern Virginia Medical School
- Emory University
- Fred Hutchinson Cancer Center
- National Cancer Institute
- Prostate Cancer Foundation
- Stanford University
- University of British Columbia
- University of Michigan
- University of Texas at Austin
- University of Washington
- Winship Cancer Institute